Rotondo C, Busto G, Rella V, Barile R, Cacciapaglia F, Fornaro M
Diagnostics (Basel). 2025; 15(4).
PMID: 40002639
PMC: 11854868.
DOI: 10.3390/diagnostics15040488.
Gutierrez M, Bertolazzi C, Zozoaga-Velazquez E, Clavijo-Cornejo D
Tomography. 2024; 10(4):521-532.
PMID: 38668398
PMC: 11054173.
DOI: 10.3390/tomography10040041.
Petelytska L, Bonomi F, Cannistra C, Fiorentini E, Peretti S, Torracchi S
RMD Open. 2023; 9(4).
PMID: 37940340
PMC: 10632935.
DOI: 10.1136/rmdopen-2023-003426.
Martin-Lopez M, Carreira P
J Clin Med. 2023; 12(20).
PMID: 37892818
PMC: 10607647.
DOI: 10.3390/jcm12206680.
van de Zande S, Abdulle A, Al-Adwi Y, Stel A, de Leeuw K, Brouwer E
Diagnostics (Basel). 2023; 13(13).
PMID: 37443554
PMC: 10340274.
DOI: 10.3390/diagnostics13132160.
Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia.
Carbone R, Monselise A, Barisione E, Fontana V, Paredi P, Puppo F
Intern Emerg Med. 2023; 18(4):1087-1093.
PMID: 37069417
DOI: 10.1007/s11739-023-03267-y.
Progressive pulmonary fibrosis: an expert group consensus statement.
Rajan S, Cottin V, Dhar R, Danoff S, Flaherty K, Brown K
Eur Respir J. 2022; 61(3).
PMID: 36517177
PMC: 10060665.
DOI: 10.1183/13993003.03187-2021.
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.
Khanna D, Distler O, Cottin V, Brown K, Chung L, Goldin J
J Scleroderma Relat Disord. 2022; 7(3):168-178.
PMID: 36211204
PMC: 9537704.
DOI: 10.1177/23971983211064463.
Serum microRNAs in Systemic Sclerosis, Associations with Digital Vasculopathy and Lung Involvement.
Wajda A, Walczyk M, Dudek E, Stypinska B, Lewandowska A, Romanowska-Prochnicka K
Int J Mol Sci. 2022; 23(18).
PMID: 36142646
PMC: 9503032.
DOI: 10.3390/ijms231810731.
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.
Denton C, Goh N, Humphries S, Maher T, Spiera R, Devaraj A
Rheumatology (Oxford). 2022; 62(5):1870-1876.
PMID: 36111858
PMC: 10152288.
DOI: 10.1093/rheumatology/keac535.
Pulmonary function and chest computed tomography abnormalities 6-12 months after recovery from COVID-19: a systematic review and meta-analysis.
Lee J, Yim J, Park J
Respir Res. 2022; 23(1):233.
PMID: 36068582
PMC: 9446643.
DOI: 10.1186/s12931-022-02163-x.
Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines.
Giordano N, Corallo C, Chirico C, Brazzi A, Marinetti A, Fioravanti A
J Scleroderma Relat Disord. 2022; 4(1):35-42.
PMID: 35382146
PMC: 8922580.
DOI: 10.1177/2397198318808998.
Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis-Interstitial Lung Disease: A Systematic Review.
Landini N, Orlandi M, Bruni C, Carlesi E, Nardi C, Calistri L
Front Med (Lausanne). 2022; 8:807982.
PMID: 35155484
PMC: 8829727.
DOI: 10.3389/fmed.2021.807982.
High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients.
Ruaro B, Baratella E, Confalonieri P, Wade B, Marrocchio C, Geri P
Diagnostics (Basel). 2021; 11(11).
PMID: 34829307
PMC: 8617987.
DOI: 10.3390/diagnostics11111960.
Comparison of diffusing capacity of carbon monoxide (DLCO) and total lung capacity (TLC) between Indigenous Australians and Australian Caucasian adults.
Howarth T, Ben Saad H, Perez A, Atos C, White E, Heraganahally S
PLoS One. 2021; 16(4):e0248900.
PMID: 33798242
PMC: 8018646.
DOI: 10.1371/journal.pone.0248900.
F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study.
Ledoult E, Morelle M, Soussan M, Mekinian A, Behal H, Sobanski V
Arthritis Res Ther. 2021; 23(1):76.
PMID: 33673861
PMC: 7936499.
DOI: 10.1186/s13075-021-02460-8.
Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review.
Hoffmann-Vold A, Maher T, Philpot E, Ashrafzadeh A, Distler O
ERJ Open Res. 2021; 7(1).
PMID: 33644224
PMC: 7897846.
DOI: 10.1183/23120541.00235-2020.
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases.
Nucera V, Gerratana E, Giallanza M, La Corte L, Sangari D, Atzeni F
Drugs Context. 2021; 10.
PMID: 33505481
PMC: 7813436.
DOI: 10.7573/dic.2020-9-1.
Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases-Network-analyses and multivariate models.
Lang D, Akbari K, Walcherberger S, Hergan B, Horner A, Hepp M
Chron Respir Dis. 2020; 17:1479973120967025.
PMID: 33272023
PMC: 7720309.
DOI: 10.1177/1479973120967025.
Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies.
Ceribelli A, Isailovic N, De Santis M, Gorlino C, Satoh M, Selmi C
J Transl Autoimmun. 2020; 3:100049.
PMID: 32743530
PMC: 7388402.
DOI: 10.1016/j.jtauto.2020.100049.